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Figure 1. An overview of the WHO classiﬁcation of non–small cell lung carcinomas on biopsy specimens is given. On the right
side, the group of NSCCs with positive NE IHC markers, which is not addressed in the 2015 WHO classiﬁcation, is presented.
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Immunohistochemical
Markers Should Not Be
Performed in Poorly
Differentiated NSCCs in the
Absence of Neuroendocrine
Morphologic Features
according to the 2015 WHO
ClassiﬁcationIn Response:
In contrast to the recommendations of the 2015 World
Health Organization (WHO) classiﬁcation of tumors,1Derks et al. suggest that testing for neuroendocrine
(NE) immunohistochemical markers should be
performed on all poorly differentiated non–small cell
carcinomas (NSCCs) lacking NE morphologic features
and reported.2 We considered this suggestion in our
preparation of the WHO classiﬁcation, and the topic
was discussed in detail. For the 2011 International
Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society lung
adenocarcinoma classiﬁcation, we conducted an
evidence-based review that addressed this topic specif-
ically.3 Because there are no consistent evidence-based
data in the literature to support any clinical relevance
(diagnostic, prognostic, or therapeutic) of a positive NE
marker in the absence of NE morphologic features, the
2015 WHO Classiﬁcation recommends that testing for
NE markers not be performed on all poorly differenti-
ated NSCCs in the absence of NE morphologic features.1
This recommendation is speciﬁcally presented on
page 20 of the WHO blue book,1 and this detail could
not be included in the short review provided for
the Journal of Thoracic Oncology.4 Only if there is a
suggestion of NE morphologic features is testing for
NE immunohistochemical markers appropriate. In
addition, the problem of NSCC with NE differentiation
February 2016 Letters to the Editor e27is addressed on page 71 of the WHO blue book, where it
also stated that NE stains are not recommended
for routine use in tumors lacking NE morphologic
features.1 The WHO committee did not consider this
problem important enough to warrant a formal title in
the classiﬁcation; however, the recommendation that
testing for NE immunohistochemical markers in the
absence of NE morphologic features not be performed
in either the nonresection or resection specimen
settings is important and should not be overlooked.
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Mesothelioma—More Than
Asbestos ExposureTo the Editor:
A combination of pathogenic organisms, environmental
carcinogen, and genetic predisposition can contribute
to carcinogenesis. No causative viruses for mesotheli-
oma have been identiﬁed to date, and even though
mesothelioma has been attributed largely to asbestos
exposure, the genetic basis underlying the disease has
lately received attention. Such interest is warranted
because asbestos alone cannot explain the varying
incidence of mesothelioma among patients with com-
parable exposure, and most diseases have a multifac-
torial etiology.
Thus, researchers were excited to ﬁnd that mutations
in a tumor suppressor gene, breast cancer 1–associated
protein 1 (BAP1), were found in families with a high
incidence of mesothelioma, as well as in sporadic cases.1Interestingly, both germline and somatic mutations were
found, which indicated a possible inheritance of the
disease, as well as establishment of BAP1 as a target of
mutations. All family members had nonoccupational,
residential asbestos exposure; thus, the relationship
between BAP1 mutations and asbestos might be
additive, synergistic, or both.
Recently, Nasu et al.2 found somatic mutations of
BAP1 in more than 60% of 22 frozen mesothelioma
biopsies, and they duplicated their ﬁnding in another 70
biopsy samples. There was no signiﬁcant correlation
between frequency of BAP1 mutations and asbestos
exposure among patients, which implied that the
pathogenesis of mesothelioma may be multifactorial and
possibly polygenic.
For instance, germline and somatic mutations in
transcriptional regulators such as mammalian switch/
sucrose nonfermentable (mSWI/SNF) chromatin
remodeling complex were noted in mesothelioma.3
Such mutations may cause low acetylation of histone
and affect transcription, thereby contributing to the
development of mesothelioma. Even though these
results were obtained from eight mesothelioma cell
lines from patients who all had a history of asbestos
exposure, they supported interplay between genetic
predisposition and asbestos as a contributor to
development of disease.
Furthermore, somatic mutations were reported in
tumor suppressor genes, including neuroﬁbroma-
tosis type 2 (NF2), large tumor suppressor 2 (LATS2),
